Compare Amgen, Inc. (AMGN) vs Atmos Energy Corporation (ATO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Atmos Energy Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Atmos Energy Corporation trades at $176.2 (market cap $29.41B). The key difference: Amgen, Inc. is far larger — about 6.7× Atmos Energy Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | ATO | |
|---|---|---|
Market Cap | $196.12B | $29.41B |
Sector | Health | Utilities |
52-Week High | $388.16 | $192.25 |
52-Week Low | $271.18 | $154.10 |
Enterprise Value | $241.41B | $38.91B |
Dividend Yield | 2.77% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Atmos Energy (ATO) trades at $176.2, up 0.85% today, with a neutral technical signal. The stock shows strong fundamentals with revenue growth to $4.70B in 2025 and a net income margin of 27.58%. Recent Q1 2026 earnings beat expectations, and the company maintains a solid dividend. Analyst consensus is a Buy with a $189.67 price target, though technical indicators suggest near-term consolidation around key support and resistance levels.
The outlook for ATO is positive due to steady earnings growth, customer expansion, and supportive regulatory changes. Risks include high capital expenditures and exposure to energy market volatility. Institutional sentiment is bullish, with no sell ratings, positioning the stock for potential upside if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →
